Answers are grounded in this paper and cite their sources.
Clinical non-remission in rheumatoid arthritis (RA) can persist despite treatment-induced suppression of immune activity. Single-cell, spatial, and longitudinal biopsy studies suggest that incomplete normalization of synovial stromal and vascular compartments may contribute to this discordance in some patients. Fibroblast-rich signatures have been associated with multidrug refractoriness, while a small longitudinal spatial study identified cartilage oligomeric matrix protein (COMP) high fibrogenic regions associated with failure to achieve remission after six months of therapy. Endothelial Notch signaling regulates fibroblast positional identity and the spatial distribution of transforming growth factor-β (TGF-β) responsiveness; perturbation studies support these interactions but do not establish that they cause therapeutic failure in patients. Separate longitudinal evidence links treatment response to restoration of a perivascular lymphatic vessel endothelial hyaluronan receptor 1 (LYVE1)-positive macrophage network. We critically examine these findings and propose a provisional “stromal-lock” model in which continued niche-dependent reinforcement may impede synovial reorganization during treatment. The model differs from fibroblast-intrinsic inflammatory memory by locating persistence within an interacting stromal-vascular-matrix environment, but its self-maintaining properties and clinical relevance remain unproven. We distinguish fibrogenic, immune-organizing, and purinergic receptor-enriched fibroblast programs without assuming separate lineages or successive activation stages. We also assess residual inflammation, structural damage, and pain amplification as alternative explanations for non-remission. Translation requires reproducible tissue assays, prospective outcome validation, and selective interventions that preserve physiological repair. Spatial niches currently provide candidate mechanisms and biomarkers, rather than validated indications for treatment selection or escalation.
No takes yet. Share an insight, caveat, or question.
Bagheri‐Hosseinabadi et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: